lung cancer
Conditions
Interventions
Observation group:Camrelizumab
Sponsors
Affiliated Cancer Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients with advanced lung cancer diagnosed by pathology or clinical diagnosis; 2. Have measurable tumor lesions (spiral CT scan >=10mm, meeting RECIST 1.1 criteria); 3. Expected survival > 3 months; 4. Aged 18 to 70 years old, male or female; 5. ECOG PS 0-2 points; 6. The functions of vital organs meet the following requirements: (1) Absolute neutrophil count >=1.5x10^9/L, platelets >=100x10^9/L, hemoglobin >=9g/dL; (2) Bilirubin 35g/ml, prothrombin time prolongation 60 mL/min; 7. Women of childbearing age must have a negative pregnancy test (ßHCG) before starting treatment, and women of childbearing age and men (having sex with women of childbearing age) must agree to use effective without interruption during treatment and for 6 months after the last therapeutic dose contraceptive measures; 8. The physician believes that it may benefit from camrelizumab treatment and accepts the treatment voluntarily; 9. The patients voluntarily joined the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Suffered from other malignant tumors in the past or at the same time, except for cured skin basal cell carcinoma and cervical carcinoma in situ. 2. There is active tuberculosis infection. Patients with active pulmonary tuberculosis infection within 1 year before the medication should be excluded even if they have been treated.Patients with a history of active pulmonary tuberculosis infection more than 1 year ago are also excluded, unless it is proven that they have previously received standard anti-tuberculosis treatment. 3. Observed patients with active, known or suspected autoimmune diseases, hypothyroidism that only needs hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) Can be selected. 4. Patients whose adverse reactions of the last treatment plan did not return to Grade 1 or normal. 5. Congestive heart failure, uncontrollable arrhythmia, myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months. 6. Patients receiving hematopoietic stem cell or organ transplantation. 7. Live vaccines have been vaccinated or will be vaccinated within 30 days before the administration of camrelizumab. 8. Pregnant or lactating women. 9. Patients who cannot comply with the trial protocol or cannot cooperate with follow-up. 10. There is a history of psychotropic drug abuse, alcohol or drug abuse. 11. Human immunodeficiency virus (HIV, HIV 1/2 antibody) positive. 12. The researcher thinks it is inappropriate to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune inspection index; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate;progression-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactWang Xiaohong
The Affiliated Cancer Hospital of Harbin Medical University
Outcome results
None listed